TMO
Thermo Fisher Scientific Inc.
—
464.61 $
+2.9200 (%+0.63)
Previous Close: 461.69
Day Low₺459.02
Day High₺467.94
TMO: Thermo Fisher Scientific Inc. Financials
TMO Income Statement
Total revenue
Net income
Gross margin TTM
37.66%
Operating margin TTM
18.2%
Net profit margin TTM
15.12%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 44,556,000,000 | 42,879,000,000 | 42,857,000,000 | 44,915,000,000 |
| Operating income | 8,109,000,000 | 7,662,000,000 | 7,446,000,000 | 8,525,000,000 |
| Net income | 6,737,000,000 | 6,335,000,000 | 5,995,000,000 | 6,950,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 44,556,000,000 | 42,879,000,000 | 42,857,000,000 | 44,915,000,000 |
| Cost of revenue | 27,778,000,000 | 25,151,000,000 | 25,663,000,000 | 25,904,000,000 |
| Gross profit | 16,778,000,000 | 17,728,000,000 | 17,194,000,000 | 19,011,000,000 |
| Research and development expenses | 1,397,000,000 | 1,390,000,000 | 1,337,000,000 | 1,471,000,000 |
| General and administrative expenses | 0 | 0 | 0 | 0 |
| Selling and marketing expenses | 0 | 0 | 0 | 0 |
| Selling, general and administrative expenses | 7,272,000,000 | 8,676,000,000 | 8,411,000,000 | 9,015,000,000 |
| Other expenses | 0 | 0 | 0 | 0 |
| Operating expenses | 8,669,000,000 | 10,066,000,000 | 9,748,000,000 | 10,486,000,000 |
| Cost and expenses | 36,447,000,000 | 35,217,000,000 | 35,411,000,000 | 36,390,000,000 |
| Net interest income | -426,000,000 | -576,000,000 | -612,000,000 | -454,000,000 |
| Interest income | 993,000,000 | 1,078,000,000 | 879,000,000 | 272,000,000 |
| Interest expense | 1,419,000,000 | 1,654,000,000 | 1,491,000,000 | 726,000,000 |
| Depreciation and amortization | 2,780,000,000 | 3,108,000,000 | 3,406,000,000 | 3,381,000,000 |
| EBITDA | 11,466,000,000 | 11,800,000,000 | 11,195,000,000 | 11,942,000,000 |
| EBIT | 8,686,000,000 | 8,692,000,000 | 7,789,000,000 | 8,561,000,000 |
| Non-operating income (excl. interest) | -577,000,000 | -1,030,000,000 | -343,000,000 | -36,000,000 |
| Operating income | 8,109,000,000 | 7,662,000,000 | 7,446,000,000 | 8,525,000,000 |
| Total other income/expenses (net) | -842,000,000 | -667,000,000 | -1,207,000,000 | -862,000,000 |
| Income before tax | 7,267,000,000 | 6,995,000,000 | 6,239,000,000 | 7,663,000,000 |
| Income tax expense | 547,000,000 | 657,000,000 | 284,000,000 | 703,000,000 |
| Net income from continuing operations | 6,720,000,000 | 6,338,000,000 | 5,955,000,000 | 6,960,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 34,000,000 | 0 | 0 | 0 |
| Net income | 6,737,000,000 | 6,335,000,000 | 5,995,000,000 | 6,950,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 6,704,000,000 | 6,335,000,000 | 5,995,000,000 | 6,950,000,000 |
| EPS | 18 | 17 | 16 | 18 |
| Diluted EPS | 18 | 17 | 15 | 18 |
| Weighted average shares outstanding | 376,000,000 | 382,000,000 | 386,000,000 | 392,000,000 |
| Weighted average diluted shares outstanding | 377,000,000 | 383,000,000 | 388,000,000 | 394,000,000 |